BioNTech, DualityBiologics' Late-Stage Trial of Metastatic Breast Cancer Therapy Meets Primary Endpoint; Severe, Fatal Events Reported

MT Newswires Live10-26 17:35

BioNTech (BNTX) and DualityBiologics' phase 3 trial of trastuzumab pamirtecan in metastatic breast cancer achieved its primary endpoint of demonstrating a statistically significant improvement in progression-free survival, but with severe and fatal events, the companies said Monday.

Data on the secondary endpoint of overall survival were not yet mature as of the interim analysis, the companies said.

Severe and fatal events were reported in a "small proportion of patients," along with a higher rate of interstitial lung disease compared with previous trials, they added.

The companies plan to discuss the data and decide on their next steps, according to the statement.

Shares of BioNTech were down more than 2% in premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment